SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection at Divi's Laboratories’ Unit-II facility in Chippada

17 Jun 2019 Evaluate

US Food and Drug Administration (USFDA) has completed inspection at Divi's Laboratories’ Unit-II at village Chippada, Bheemunipatnam District in the state of Andhra Pradesh (AP). The inspection was conducted from June 10 to 15, 2019.

This was a general CGMP inspection by the US-FDA. The inspection has been concluded with no 483 observations.

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

Divis Lab Share Price

6378.75 90.30 (1.44%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×